Compare · AXGN vs BLFS
AXGN vs BLFS
Side-by-side comparison of Axogen Inc. (AXGN) and BioLife Solutions Inc. (BLFS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and BLFS operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- AXGN is the larger of the two at $2.06B, about 1.1x BLFS ($1.89B).
- Over the past year, AXGN is up 106.6% and BLFS is up 39.4% - AXGN leads by 67.2 points.
- BLFS has been more active in the news (29 items in the past 4 weeks vs 6 for AXGN).
- AXGN has more recent analyst coverage (11 ratings vs 9 for BLFS).
- Company
- Axogen Inc.
- BioLife Solutions Inc.
- Price
- -
- -
- Market cap
- $2.06B
- $1.89B
- 1M return
- -23.49%
- +8.67%
- 1Y return
- +106.59%
- +39.38%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 6
- 29
- Recent ratings
- 11
- 9
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
BioLife Solutions Inc.
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
Latest AXGN
- Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
- BofA Securities initiated coverage on AxoGen with a new price target
- Barclays initiated coverage on AxoGen with a new price target
- Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
- Axogen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
- SEC Form 424B5 filed by Axogen Inc.
- Amendment: Axogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
Latest BLFS
- SEC Form 15-12G filed by BioLife Solutions Inc.
- SEC Form EFFECT filed by BioLife Solutions Inc.
- SEC Form EFFECT filed by BioLife Solutions Inc.
- SEC Form 4 filed by BioLife Solutions Inc.
- SEC Form 4 filed by BioLife Solutions Inc.
- SEC Form 4 filed by BioLife Solutions Inc.
- SEC Form 4 filed by BioLife Solutions Inc.
- SEC Form 4 filed by BioLife Solutions Inc.
- SEC Form 4 filed by BioLife Solutions Inc.
- SEC Form 4 filed by BioLife Solutions Inc.